-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Viral -X- _ B-Intervention
protein -X- _ I-Intervention
R -X- _ I-Intervention
( -X- _ I-Intervention
Vpr -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
a -X- _ O
protein -X- _ O
of -X- _ O
human -X- _ O
immunodeficiency -X- _ O
virus -X- _ O
type-1 -X- _ O
( -X- _ O
HIV-1 -X- _ O
) -X- _ O
with -X- _ O
various -X- _ O
biological -X- _ O
functions -X- _ O
, -X- _ O
was -X- _ O
shown -X- _ O
to -X- _ O
be -X- _ O
present -X- _ O
in -X- _ O
the -X- _ O
blood -X- _ O
of -X- _ O
HIV-1-positive -X- _ B-Patient
patients. -X- _ I-Patient
However -X- _ O
, -X- _ O
it -X- _ O
remained -X- _ O
unclear -X- _ O
whether -X- _ O
circulating -X- _ O
Vpr -X- _ O
in -X- _ O
patients’ -X- _ O
blood -X- _ O
is -X- _ O
biologically -X- _ O
active. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
examined -X- _ O
the -X- _ O
activity -X- _ O
of -X- _ O
blood -X- _ O
Vpr -X- _ O
using -X- _ O
an -X- _ O
assay -X- _ O
system -X- _ O
by -X- _ O
which -X- _ O
retrotransposition -X- _ B-Outcome
of -X- _ I-Outcome
long -X- _ I-Outcome
interspersed -X- _ I-Outcome
element-1 -X- _ I-Outcome
( -X- _ I-Outcome
L1-RTP -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
detected. -X- _ I-Outcome
We -X- _ O
also -X- _ O
investigated -X- _ O
the -X- _ O
in -X- _ O
vivo -X- _ O
effects -X- _ O
of -X- _ O
recombinant -X- _ B-Intervention
Vpr -X- _ I-Intervention
( -X- _ I-Intervention
rVpr -X- _ I-Intervention
) -X- _ I-Intervention
by -X- _ O
administrating -X- _ O
it -X- _ O
to -X- _ O
transgenic -X- _ B-Patient
mice -X- _ I-Patient
harboring -X- _ I-Patient
human -X- _ I-Patient
L1 -X- _ I-Patient
as -X- _ I-Patient
a -X- _ I-Patient
transgene -X- _ I-Patient
( -X- _ O
hL1-Tg -X- _ O
mice -X- _ O
) -X- _ O
. -X- _ O
Based -X- _ O
on -X- _ O
our -X- _ O
data -X- _ O
, -X- _ O
we -X- _ O
discuss -X- _ O
the -X- _ O
involvement -X- _ O
of -X- _ O
blood -X- _ B-Intervention
Vpr -X- _ I-Intervention
in -X- _ O
the -X- _ O
clinical -X- _ O
symptoms -X- _ O
of -X- _ O
acquired -X- _ O
immunodeficiency -X- _ O
syndrome -X- _ O
( -X- _ O
AIDS -X- _ O
) -X- _ O
. -X- _ O

RESULTS -X- _ O
: -X- _ O
We -X- _ O
first -X- _ O
discovered -X- _ O
that -X- _ O
rVpr -X- _ B-Outcome
was -X- _ I-Outcome
active -X- _ I-Outcome
in -X- _ I-Outcome
induction -X- _ I-Outcome
of -X- _ I-Outcome
L1-RTP. -X- _ I-Outcome
Biochemical -X- _ I-Outcome
analyses -X- _ I-Outcome
revealed -X- _ I-Outcome
that -X- _ I-Outcome
rVpr-induced -X- _ I-Outcome
L1-RTP -X- _ I-Outcome
depended -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
aryl -X- _ I-Outcome
hydrocarbon -X- _ I-Outcome
receptor -X- _ I-Outcome
, -X- _ I-Outcome
mitogen-activated -X- _ I-Outcome
protein -X- _ I-Outcome
kinases -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
CCAAT -X- _ I-Outcome
/ -X- _ I-Outcome
enhancer-binding -X- _ I-Outcome
protein -X- _ I-Outcome
β. -X- _ I-Outcome
By -X- _ I-Outcome
using -X- _ I-Outcome
a -X- _ I-Outcome
sensitive -X- _ I-Outcome
L1-RTP -X- _ I-Outcome
assay -X- _ I-Outcome
system -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
6 -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
15 -X- _ I-Outcome
blood -X- _ I-Outcome
samples -X- _ I-Outcome
from -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
patients -X- _ I-Outcome
examined -X- _ I-Outcome
were -X- _ I-Outcome
positive -X- _ I-Outcome
for -X- _ I-Outcome
induction -X- _ I-Outcome
of -X- _ I-Outcome
L1-RTP. -X- _ I-Outcome
Of -X- _ I-Outcome
note -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
L1-RTP-inducing -X- _ I-Outcome
activity -X- _ I-Outcome
was -X- _ I-Outcome
blocked -X- _ I-Outcome
by -X- _ I-Outcome
a -X- _ I-Outcome
monoclonal -X- _ I-Outcome
antibody -X- _ I-Outcome
specific -X- _ I-Outcome
for -X- _ I-Outcome
Vpr. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
L1-RTP -X- _ I-Outcome
was -X- _ I-Outcome
reproducibly -X- _ I-Outcome
induced -X- _ I-Outcome
in -X- _ I-Outcome
various -X- _ I-Outcome
organs -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
the -X- _ I-Outcome
kidney -X- _ I-Outcome
, -X- _ I-Outcome
when -X- _ I-Outcome
rVpr -X- _ I-Outcome
was -X- _ I-Outcome
administered -X- _ I-Outcome
to -X- _ I-Outcome
hL1-Tg -X- _ I-Outcome
mice -X- _ I-Outcome
. -X- _ O

CONCLUSIONS -X- _ O
: -X- _ O
Blood -X- _ B-Outcome
Vpr -X- _ I-Outcome
is -X- _ I-Outcome
biologically -X- _ I-Outcome
active -X- _ I-Outcome
, -X- _ I-Outcome
suggesting -X- _ I-Outcome
that -X- _ I-Outcome
its -X- _ I-Outcome
monitoring -X- _ I-Outcome
is -X- _ I-Outcome
worthwhile -X- _ I-Outcome
for -X- _ I-Outcome
clarification -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
roles -X- _ I-Outcome
of -X- _ I-Outcome
Vpr -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
pathogenesis -X- _ I-Outcome
of -X- _ I-Outcome
AIDS. -X- _ I-Outcome
This -X- _ O
is -X- _ O
the -X- _ O
first -X- _ O
report -X- _ O
to -X- _ O
demonstrate -X- _ O
a -X- _ O
soluble -X- _ O
factor -X- _ O
in -X- _ O
patients’ -X- _ O
blood -X- _ O
active -X- _ O
for -X- _ O
L1-RTP -X- _ O
activity -X- _ O
, -X- _ O
and -X- _ O
implies -X- _ O
the -X- _ O
involvement -X- _ O
of -X- _ O
L1-RTP -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
human -X- _ O
diseases -X- _ O
. -X- _ O

